Coenzyme Q10 and Adverse Effects of Statins

References

• ACC/AHA/NHLBI Clinical Advisory on Statins: clinical advisory on the use and safety of statins.JACC 2002; 40: 567–72.
   Google Scholar
• Chong P, Seeger J, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001; 111: 390–400.
   PubMed Web of Science ®Google Scholar
• Bliznakov EG. Lipid lowering drugs (statins), cholesterol, and coenzyme Q10—The Baycol case—a modern Pandora’s box. Biomed Pharmacother 2002; 56: 56–9.
   PubMed Web of Science ®Google Scholar
• Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid lowering drugs and risk of myopathy: a population based follow up study. Epidemiology 2001; 12: 565–9.
   PubMed Web of Science ®Google Scholar
• Staffa JA, Green L. Cerivastatin and reports of rhabdomyolysis. N Engl J Med 2002; 346: 565–70.
   Web of Science ®Google Scholar
• Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–31.
   PubMed Web of Science ®Google Scholar
• Gaist D, Jeppesen U, Anderson M et al. Statins and risk of poluneuropathy: a case control study.Neurology 2002; 58: 1333–7.
   Google Scholar
• Farmer JA. Learning from the cerivastatin experience. Lancet 2001; 358: 1383–5.
   PubMed Web of Science ®Google Scholar
• Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin– gemphibrozil combination therapy. JAMA 1990; 264: 71–5.
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Saf 1996; 14: 11–24.
   PubMed Web of Science ®Google Scholar
• Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitors monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995; 29: 743–59.
   PubMed Web of Science ®Google Scholar
• Cleeman JI. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486–97.
   Google Scholar
• Pella D, Singh RB, Tomlinson B, Kong CW. Coronary artery disease in developing and newly industrialized countries: a scientific statement of the International College of Cardiology. In: Choklingham A, Berkowitz I, Singal PK, Dhalla NS (eds) Frontiers in Cardiovascular Health. Boston: Kluwer, 2003, 473–88.
   Google Scholar
• Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22.
   Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–7.
   Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001–9.
   Google Scholar
• LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a metaanalysis of randomized, controlled trials. JAMA 1999; 282: 2340–6.
   PubMed Web of Science ®Google Scholar
• Scandinavian Simstatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.
   PubMed Web of Science ®Google Scholar
• Longterm Intervention with Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Longterm Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 2003; 339: 1349–57.
   Google Scholar
• Shepherd Jthe PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized, controlled trial. Lancet 2002; 360: 1623–30.
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of individuals: cholesterol lowering with simvastatin in 20,536 high-risk a randomized, placebo controlled trial. Lancet 2002; 360: 7–22.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Katamaki T, Waxman DL et al. The P 450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol 1993; 12: 1–51.
   PubMed Web of Science ®Google Scholar
• Nebert DW. The P 450 superfamily: update on new sequences, gene mapping and recommended nomenclature. DNA Cell Biol 1991; 10: 1–14.
   PubMed Web of Science ®Google Scholar
• London SF, Gross KF, Ringel SP. Cholesterol lowering agent myopathy. Neurology 1991; 41: 1159–60.
   PubMed Web of Science ®Google Scholar
• Mortensen SA, Leth A, Agner E et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG CoA reductase inhibitors. Mol Aspects Med 1997; 18 (Suppl. S): S137–44.
   Google Scholar
• Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1984; 144: 1045–57.
   Google Scholar
• Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–46.
   Google Scholar
• Ballantyne CM. Evolving concepts and new approach for management of hyperlipidemia. Eur Heart J 2002; 4(Suppl. J): J1–3.
   Google Scholar
• Pella D, Ryba´ r R, Valocˇik G, Petra´ sˇova´ D, Trejbal D, Mitro P. Secondary prevention of atherosclerosis by combined treatment with sulodexide and fluvastatin. Cardiovascular Diseases. Bologna: Monduzzi Editore, 2002, 289–93.
   Google Scholar
• de Lorgeril M, Salen P, Martin JL et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779–85.
   Google Scholar
• Singh RB, Dubnov O, Niaz MA et al. The effect of an Indo-Mediterranean diet on the progression of coronary artery disease in high risk patients. The Indo-Mediterranean Diet Heart Study. Lancet 2002; 360: 1455–61.
   Google Scholar
• Hoerger JG. US National Health and Nutrition Examination Survey III. Am J Cardiol 1998; 82: 61–5.
   PubMed Web of Science ®Google Scholar
• Singh RB, Neki NS, Kartikey K, Pella D et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem 2003; 246: 75–82.
   Google Scholar
• Editorial. How a statin might destroy a drug company. Lancet 2003; 361: 793.
   Google Scholar